Kolon TissueGene, Inc. Logo

Kolon TissueGene, Inc.

Developing cell and gene therapies for orthopedic and degenerative disorders.

950160 | KO

Overview

Corporate Details

ISIN(s):
KR8840120008
LEI:
Country:
United States of America
Address:
9713 Key West Ave Suite 300, Rockville
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, disease-modifying allogeneic cell therapy for the treatment of knee osteoarthritis. This innovative therapy is designed to reduce pain, improve joint function, and potentially slow disease progression. Kolon TissueGene is advancing TG-C through late-stage clinical trials and exploring the application of its platform technology for other degenerative conditions, such as spinal diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 88.5 KB
2025-09-11 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 20.0 KB
2025-09-10 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 13.9 KB
2025-09-09 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 19.1 KB
2025-09-04 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 18.6 KB
2025-08-27 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 18.7 KB
2025-08-14 00:00
Capital/Financing Update
파생상품거래손실발생
Korean 7.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-07-28 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사
Korean 13.1 KB
2025-07-24 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 20.3 KB
2025-07-22 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 16.7 KB
2025-07-14 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (기술수출 계약 체결(당사의 라이센시인 코오롱생명과학㈜ 주요경영사항))
Korean 17.9 KB
2025-07-11 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사 (제2회차)
Korean 11.8 KB
2025-07-10 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 16.2 KB
2025-07-10 00:00
Share Issue/Capital Change
전환청구권행사 (제2회차)
Korean 8.7 KB

Automate Your Workflow. Get a real-time feed of all Kolon TissueGene, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kolon TissueGene, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kolon TissueGene, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Gencurix Inc. Logo
Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.
South Korea
229000
GENELUX Corp Logo
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
United States of America
GNLX
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea
109820
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America
GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea
011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America
GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway
GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France
GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America
GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye
GENIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.